{"url_path":"/sec/slno/8-k/2026-05-18/item-9-01","section_key":"item-9-01","section_title":"Item 9.01 Financial Statements and Exhibits.","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-05-18","source_url":"https://www.sec.gov/Archives/edgar/data/1484565/0001193125-26-228016-index.html","accession_number":"0001193125-26-228016","cik":"0001484565","ticker":"SLNO","issuer_name":"SOLENO THERAPEUTICS INC","edgar_url":"https://www.sec.gov/Archives/edgar/data/1484565/0001193125-26-228016-index.html","primary_entity_key":"0001484565","primary_entity_name":"SOLENO THERAPEUTICS INC"},"word_count":205,"has_tables":true,"body_markdown":"Item 9.01\n\nFinancial Statements and Exhibits.\n\n(d) Exhibits\n\n \n\nExhibit\nNo.\n\n  \n\nDescription\n\n2.1*\n  \n[Agreement and Plan of Merger, dated as of April 5, 2026, by and among Soleno Therapeutics, Inc., Neurocrine Biosciences, Inc., and Sigma Merger Sub, Inc. (incorporated by reference to Exhibit 2.1 to the Company’s Current Report on Form 8-K filed with the SEC on April 6, 2026).](http://www.sec.gov/Archives/edgar/data/1484565/000119312526142911/d142985dex21.htm)\n\n3.1\n  \n[Amended and Restated Certificate of Incorporation of Soleno Therapeutics, Inc.](d143266dex31.htm)\n\n3.2\n  \n[Amended and Restated Bylaws of Soleno Therapeutics, Inc.](d143266dex32.htm)\n\n104\n  \nCover Page Interactive Data File (embedded within the Inline XBRL document).\n\n \n\n*\n\nCertain annexes and schedules have been omitted pursuant to Item 601(a)(5) of Regulation S-K. The Company hereby undertakes to furnish supplemental copies of any of the omitted annexes and schedules upon request by the SEC; provided, however, that the Company may request confidential treatment pursuant to Rule 24b-2 of the Securities and Exchange Act of 1934 for any annexes or schedules so furnished.\n\nSIGNATURE\n\nPursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.\n\nDated: May 18, 2026\n\n \n\nSOLENO THERAPEUTICS, INC.\n\nBy:\n\n \n\n/s/ Darin M. Lippoldt\n\nName:\n\n \n\nDarin M. Lippoldt\n\nTitle:\n\n \n\nPresident and Secretary"}